

Cancer Cell Analysis, Instruments, Consumables and Reagents

<https://marketpublishers.com/r/CE095B09B86EN.html>

Date: December 2018

Pages: 235

Price: US\$ 1,375.00 (Single User License)

ID: CE095B09B86EN

Abstracts

Report Scope:

The scope of this report is broad and covers product type, end users, techniques and applications of cancer cell analysis instruments and consumables. Revenue forecasts from 2018 through 2023 are given for each of the segments and regional markets with estimated values derived from the manufacturers' total revenues.

The report also includes a discussion of the major players across each region and explains the major drivers and regional dynamics of the global cancer cell analysis market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors.

Report Includes:

100 data tables and 91 additional tables

Detailed overview of the global market for cancer cell analysis in instruments, reagents and consumables

Analyses of the global market trends with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023

Qualitative and quantitative study of the cancer cell analysis industry by product type, end user, analyses technique, application

Assessment of the major drivers and regional dynamics of the global cancer cell analysis market and current trends within the industry

Emphasis on the vendor landscape and detailed profiles of the major vendors in the cancer cell analysis market, including Abbott Laboratories, Bio-Rad Laboratories Inc., GE Healthcare, Merck Millipore, QIAGEN Inc., Siemens Healthcare and ThermoFischer Scientific

Contents

CHAPTER 1 INTRODUCTION=

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS=

CHAPTER 3 MARKET OVERVIEW=

Introduction
Current Technologies, Trends and Advancements
Industry Growth Drivers
Rising Incidences of Different Types of Cancers Across the Globe
Surging Investment for Cancer-Based Research
Growing Importance of Cell Assay-Based Drug Development
Increasing Demand for the Development of Personalized Medicine for Cancer
Advancements in Stem Cell Analysis and Biomarker Technology

CHAPTER 4 MARKET BREAKDOWN BY TECHNOLOGY TYPE=

Consumables
Reagents
Assay Kits
Media
Microplates
Others (Beads and Blocking Sera)
Instruments
Cytometers
Spectrophotometer
Cell Counters

Cell Isolation and Separation Instruments
Microscopes
Cell Microarrays
Quantitative PCR
Others

CHAPTER 5 MARKET BREAKDOWN BY END USER=

Pharma and Biotech Companies
Increasing Cancer Prevalence: A Key Opportunity Provider
Cell Therapy
Contract Research Organizations (CROs)
Research and Academic Institutes
Basic Cancer Research
Translational Research
Clinical Research
Clinical Trials
Laboratories and Hospitals
Blood Chemistry Test
Complete Blood Count (CBC)
Cytogenetic Analysis
Immunophenotyping
Sputum Cytology
Tumor Marker Tests

CHAPTER 6 MARKET BREAKDOWN BY TECHNIQUE=

Molecular Approach
Polymerase Chain Reaction (PCR)
NGS (Next-Generation Sequencing)
Microfluidics
Others
Cell Imaging Approach
Fluorescent In Situ Hybridization (FISH)
Microscopy
High Content Screening
Rising Adoption and Development of Anti-Cancer Drugs
Cytometry
Others

CHAPTER 7 MARKET BREAKDOWN BY APPLICATION=

Cell Imaging
Technological Advancements in Cell Imaging
Cell Viability and Proliferation
Cell Signaling Pathways
RNA Expression
Cell Growth and Manipulation
Cell Immunotherapy
Dendritic Cell (DC) Vaccine
Tumor-Infiltrating Lymphocytes (TIL) Therapy
T Cell Receptor (TCR) Therapy
Chimeric Antigen Receptor (CAR) T cell Therapy
Flow Cytometry
Genotypic or Phenotypic Research
Drug Discovery and Development

CHAPTER 8 MARKET BREAKDOWN BY REGION=

North America
United States
Canada
Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
Europe
United Kingdom
France
Germany
Spain
Italy
Rest of Europe
ROW=
Latin America
Middle East and Africa

CHAPTER 9 INDUSTRY STRUCTURE OF GLOBAL CANCER CELL ANALYSIS MARKET=

Industry Structure and Supply Chain Analysis for Global Cancer Cell Analysis Market

R&D=

Suppliers

Manufacturers

End Users

Investment Analysis and Future Growth Prospects

CHAPTER 10 PATENT ANALYSIS=

U.S. Patent Analysis

European Patent Analysis

Japanese Patent Analysis

CHAPTER 11 COMPANY PROFILES=

ABBOTT LABORATORIES=

ACEA BIOSCIENCE INC.=

AGILENT TECHNOLOGIES INC.=

BECTON, DICKINSON AND CO.=

BIO-RAD LABORATORIES=

CELLIX LTD.=

CYNVENIO BIOSYSTEMS INC.=

DANAHER CORP.=

F. HOFFMANN-LA ROCHE AG=

FLUIDIGM CORP.=

GE HEALTHCARE=

GENSCRIPT=

INTELLICYT CORP.=

LOGOS BIOSYSTEMS=

LONZA GROUP LTD.=

LUMACYTE LLC=

MERCK MILLIPORE=

OLYMPUS CORP.=

PERKINELMER, INC.=

PROMEGA CORP.=

QIAGEN INC.=
SIEMENS HEALTHCARE GMBH=
TECAN GROUP LTD.=
THERMOFISCHER SCIENTIFIC=

TAKARA BIO

List Of Tables

LIST OF TABLES

Summary Table: Global Market for Cancer Cell Analysis, by Product Type, Through 2023

Table 1: Current Technologies Used in Cancer Cell Analysis

Table 2: Global Prevalence of Cancer, by Type, 2016

Table 3: Major Types of Cancer Prevalence, by Region, 2015 and 2016

Table 4: Investment in Cancer, by Areas of Research

Table 5: Investments in Cancer-Based Research

Table 6: Major Types of Cell-Based Assay Used in HTS for Drug Screening

Table 7: Products in Clinical Development and Regulatory Review, 2016

Table 8: Drugs in Pipeline for Selected Causes, 2017

Table 9: Specific Issues in Personalized Medicine and Cancer

Table 10: In Vivo Versus In Vitro Stem Cell Assays

Table 11: Biomarkers for Cancer Detection, Diagnosis and Prognosis

Table 12: Global Market for Cancer Cell Analysis, by Product Type, Through 2023

Table 13: Global Market Shares of the Cancer Cell Analysis, by Product Type, 2017 vs. 2023

Table 14: A Summary of Relevant Single-cell Methods and their Applications to Cancer

Table 15: Global Market for Cancer Cell Analysis, by Consumables, Through 2023

Table 16: Global Market for Consumables in Cancer Cell Analysis, by Region, Through 2023

Table 17: Global Market for Reagents, by Region, Through 2023

Table 18: Kits and Reagents for the Separation of CSCs from Various Starting Materials

Table 19: Kits and Reagents for the Separation of CTCs from Various Starting Materials

Table 20: Global Market for Assay Kits, by Region, Through 2023

Table 21: Determination of Apoptosis and Necrosis in Cancer Cells

Table 22: Summary of Intracellular Metabolic Assays Available to Measure Cellular Proliferation

Table 23: Global Market for Media, by Region, Through 2023

Table 24: The American Cancer Society's Estimate for Lung Cancer in the United States, 2018

Table 25: Global Market for Microplates, by Region, Through 2023

Table 26: Medicines in Development for Cancer, 2018

Table 27: Global Market for Other Consumables, by Region, Through 2023

Table 28: Global Market for Cancer Cell Analysis, by Instruments, Through 2023

Table 29: Global Market for Cytometers in Cancer Cell Analysis, by Type, Through 2023

- Table 30: Global Cytometer Market, by Region, Through 2023
- Table 31: Estimated Female Breast Cancer Deaths in the U.S., by Age, 2017
- Table 32: Global Spectrophotometers Market, by Region, Through 2023
- Table 33: Global Market for Cell Counters in Cancer Cell Analysis, by Type, Through 2023
- Table 34: Automatic Cell Counter Technology
- Table 35: Comparison Between Manual Cell Counters and Automated Cell Counters
- Table 36: Global Market for Cell Counters, by Region, Through 2023
- Table 37: Characteristics of Cells
- Table 38: Cell Isolation and Separation Techniques
- Table 39: Global Market for Cell Isolation and Separation Instruments, by Region, Through 2023
- Table 40: Global Market for Microscopes, by Region, Through 2023
- Table 41: Global Market for Cell Microarrays, by Region, Through 2023
- Table 42: Global Quantitative PCR Market, by Region, Through 2023
- Table 43: Global Market for Other Instruments, by Region, Through 2023
- Table 44: Global Market for Cancer Cell Analysis, by End User, Through 2023
- Table 45: Prevalence of Cancer in Major Countries, by Type, 2015
- Table 46: Ongoing Drug Developments and Trials for Cancer
- Table 47: Deaths, by Cancer in Major Countries, 2015
- Table 48: Global Market for Pharma and Biotech Companies, by Region, Through 2023
- Table 49: Technology Approvals and Advancements, by Major Players
- Table 50: CAR T-Cell Therapy in Immuno-Oncology Medicine Development, 2017
- Table 51: Development Works Initiated in CAR T Therapy
- Table 52: Global Market for Contract Research Organizations, by Region, Through 2023
- Table 53: Market Share of for Drugs Under Development, 2016
- Table 54: Some of the Major Collaborations
- Table 55: Global Market for Research Organizations and Academic Institutes, by Region, Through 2023
- Table 56: International Cancer Research Projects, by Region, 2017-2018
- Table 57: Clinical Trials in the Field of Cancer Research
- Table 58: Current Grants in the U.S., by Cancer Type, 2018
- Table 59: Investment in Cancer Research in Canada, by Cancer Type
- Table 60: Global Market for Laboratories and Hospitals, by Region, Through 2023
- Table 61: Share of Population with Cancer, by Type, 2016
- Table 62: Global Market for Cancer Cell Analysis, by Technique, Through 2023
- Table 63: Global Market for Cancer Cell Analysis Techniques, by Region, Through 2023
- Table 64: Global Market for Molecular Approach in Cancer Cell Analysis, by Application,

Through 2023

Table 65: Global Market for Molecular Approaches in Cancer Cell Analysis, by Region, Through 2023

Table 66: Global Market for PCR in Cancer Cell Analysis, by Region, Through 2023

Table 67: Global Cancer Incidence, by Year, 2005-2016

Table 68: Global Market for Next-Generation Sequencing in Cancer Cell Analysis, by Region, Through 2023

Table 69: NGS Sequencers and Sequencing Technology

Table 70: Various Enrichment Technologies for NGS

Table 71: Quality Control (QC) Metrics for Next-Generation Sequencing

Table 72: Cancer Deaths Worldwide, 2006-2016

Table 73: Global Market for Microfluidics in Cancer Cell Analysis, by Region, Through 2023

Table 74: Size-Based Cancer Cell Separation Microfluidic Devices

Table 75: Microfluidics Devices for Cancer Cell Biophysical Property Characterization

Table 76: Global Market for Other Molecular Approaches in Cancer Cell Analysis, by Region, Through 2023

Table 77: Protein Arrays for the Cancer Biomarker Discovery

Table 78: Global Market for the Cell Imaging Approach in Cancer Cell Analysis, by Region, Through 2023

Table 79: Major Growth Drivers for Global Cell Imaging Approach Market

Table 80: Global Market for the Cell Imaging Approach in Cancer Cell Analysis, by Application, Through 2023

Table 81: Global Market for FISH in Cancer Cell Analysis, by Region, Through 2023

Table 82: Application of FISH for the Study of Different Cancer Types

Table 83: Global Market for Microscopy in Cancer Cell Analysis, by Region, Through 2023

Table 84: Clinical Trials in Microscopy

Table 85: Global Market for High Content Screening in Cancer Cell Analysis, by Region, Through 2023

Table 86: Initiatives for the Development of Anti-Cancer Drugs, 2016-2018

Table 87: Global Market for Cytometry in Cancer Cell Analysis, by Region, Through 2023

Table 88: Global Deaths Due to Leukemia, 2016

Table 89: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018

Table 90: Clinical Trials in Cytometry

Table 91: Global Market for Other Cell Imaging Approaches in Cancer Cell Analysis, by Region, Through 2023

Table 92: Global Deaths Due to Breast Cancer, 2012-2016

Table 93: Global Market for Cancer Cell Analysis, by Application, Through 2023

Table 94: Global Market for Cell Imaging Application, by Region, Through 2023

Table 95: Global Market for Cell Imaging in Cancer Cell Analysis, by Region, Through 2023

Table 96: Rising Prevalence of Cancer, by Type, 2005-2015

Table 97: Global Market for Cell Viability and Proliferation in Cancer Cell Analysis, by Region, Through 2023

Table 98: Cell Viability at Various Concentrations of Anti-Cancer Drug

Table 99: Global Market for Cell Signaling Pathways in Cancer Cell Analysis, by Region, Through 2023

Table 100: National Cancer Institute (NCI) Cancer Research Funding, by Cancer Type, 2014-2016

Table 101: Global Market for RNA Expression in Cancer Cell Analysis, by Region, Through 2023

Table 102: Ongoing and Completed Clinical Trials on RNA Expression-based Cancer Cell Analysis

Table 103: Biotechnology R&D Expenditures, by Country, 2011 and 2015

Table 104: Key Differences in Normal Cells and Cancer Cells

Table 105: Global Market for Cell Growth and Manipulation in Cancer Cell Analysis, by Region, Through 2023

Table 106: In Vitro and In Vivo Studies Deploying Modified and Altered Exosomes for Effective Cancer Treatment

Table 107: Global Market for Cell Immunotherapy in Cancer Cell Analysis, by Region, Through 2023

Table 108: Global Market for Flow Cytometry in Cancer Cell Analysis, by Region, Through 2023

Table 109: Global Market for Genotypic or Phenotypic Research in Cancer Cell Analysis, by Region, Through 2023

Table 110: Active Clinical Studies Involving Genotypic or Phenotypic Cancer Research, 2015-2018

Table 111: Global Market for Drug Discovery and Development in Cancer Cell Analysis, by Region, Through 2023

Table 112: North American Market for Cancer Cell Analysis, by Country, Through 2023

Table 113: U.S. Cancer Incidence in Males, by Cancer Type, 2017

Table 114: U.S. Cancer Incidence in Females, by Cancer Type, 2017

Table 115: Current Grants, by Cancer Type, 2017

Table 116: Estimates of National Expenditures for Cancer Care, by Cancer Site, 2010-2017

- Table 117: Canadian Cancer Incidence in Males, by Cancer Type, 2017
- Table 118: Canadian Cancer Incidence in Females, by Cancer Type, 2017
- Table 119: Current Cancer Research Funding in Canada, 2018
- Table 120: Asia-Pacific Market for Cancer Cell Analysis, by Country, Through 2023
- Table 121: Cancer Prevalence Based on Incidence Rates, 2016
- Table 122: Clinical Trials for Cancer Cell Analysis
- Table 123: Commonly Diagnosed Cancers in Male, by Cancer Type, 2017
- Table 124: Commonly Diagnosed Cancers in Female, by Cancer Type, 2017
- Table 125: Percentage Change in Cancer Prevalence, 2005-2016
- Table 126: Distribution, by Cancer Type, 2015
- Table 127: Clinical Trials for Cancer Cell Analysis (Singapore)
- Table 128: European Cancer Cell Analysis Market, by Country, Through 2023
- Table 129: Estimated Number of People Living with Cancer in the U.K., by Country, 2015 and 2020
- Table 130: Site-specific Research Funding in the United Kingdom, 2015
- Table 131: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2015
- Table 132: Ongoing and Completed Clinical Trials on Cancer Cell Analysis in France
- Table 133: Estimates of Spain's Cancer Incidence in Men and Women, by Cancer Type, 2015
- Table 134: DFF-Research Projects Grants from the Danish Council for Independent Research to Promote Cancer Cell Analysis in June 2015
- Table 135: Projects Recommended to the NCU Board for Funding, 2016
- Table 136: ROW Cancer Cell Analysis Market, by Country, Through 2023
- Table 137: Brazil's New Cases of Cancer, by Gender, 2016
- Table 138: Clinical Trials in Mexico for Cancer Cell Analysis
- Table 139: Leading Causes of Death in Argentina and Percentage Change from 2005 to 2016
- Table 140: Kenya's Prevalence of Cancer, by Cancer Type, 2015 and 2016
- Table 141: M&A Deals in Life Science Sector, 2017
- Table 142: Investment Analysis
- Table 143: U.S. Cancer Cell Analysis Patent, 2018
- Table 144: European Cancer Cell Analysis Patents, 2015-2018
- Table 145: Japanese Cancer Cell Analysis Patent, 2015-2018
- Table 146: Abbott: Product Portfolio
- Table 147: Abbott: Recent Developments, 2018
- Table 148: ACEA Biosciences Inc.: Product Portfolio
- Table 149: ACEA Biosciences Inc.: Recent Developments, 2017 and 2018
- Table 150: Agilent Technology Inc.: Product Portfolio

- Table 151: Agilent Technology Inc.: Recent Developments, 2015-2017
- Table 152: Becton, Dickinson and Co.: Product Portfolio
- Table 153: Becton, Dickinson and Co.: Recent Developments, 2015-2018
- Table 154: Bio-Rad Laboratories Inc.: Product Portfolio
- Table 155: Bio-Rad Laboratories Inc.: Recent Developments, 2016 and 2017
- Table 156: Cellix Ltd.: Product Portfolio
- Table 157: Cynvenio Biosystems Inc.: Product Portfolio
- Table 158: Cynvenio Biosystems Inc.: Recent Developments, 2017 and 2018
- Table 159: Danaher Corp.: Product Portfolio
- Table 160: Danaher Corp.: Recent Developments, 2016-2018
- Table 161: F. Hoffmann-LA Roche AG: Product Portfolio
- Table 162: F. Hoffmann-LA Roche AG: Recent Developments, 2015-2017
- Table 163: Fluidigm Corp.: Product Portfolio
- Table 164: Fluidigm Corp.: Recent Developments, 2018
- Table 165: GE Healthcare: Product Portfolio
- Table 166: GE Healthcare: Recent Developments, 2017 and 2018
- Table 167: GenScript: Product Portfolio
- Table 168: Intellicyt Corp.: Product Portfolio
- Table 169: Intellicyt Corp.: Recent Developments, 2016-2018
- Table 170: Logos Biosystems: Product Portfolio
- Table 171: Ionza Group Ltd.: Product Portfolio
- Table 172: LumaCyte LLC: Product Portfolio
- Table 173: LumaCyte LLC: Recent Developments, 2016-2018
- Table 174: Merck Millipore: Product Portfolio
- Table 175: Merck Millipore: Recent Developments, 2016-2018
- Table 176: Olympus Corp.: Product Portfolio
- Table 177: Olympus Corp.: Recent Developments, 2015-2018
- Table 178: PerkinElmer Inc.: Product Portfolio
- Table 179: PerkinElmer Inc.: Recent Developments, 2015-2018
- Table 180: Promega Corp.: Product Portfolio
- Table 181: QIAGEN Inc.: Product Portfolio
- Table 182: QIAGEN Inc.: Recent Developments, 2015-2018
- Table 183: Siemens Healthcare GmbH: Product Portfolio
- Table 184: Siemens Healthcare GmbH: Recent Developments, 2016-2018
- Table 185: Tecan Group Ltd.: Product Portfolio
- Table 186: Tecan Group Ltd.: Recent Developments, 2015-2017
- Table 187: ThermoFischer Scientific: Product Portfolio
- Table 188: ThermoFischer Scientific: Recent Developments, 2017 and 2018
- Table 189: Takara Bio: Product Portfolio

Table 190: Takara Bio: Recent Developments, 2017 and 2018

List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Cancer Cell Analysis, by Product Type, 2017-2023

Figure 1: Applications of Cancer Cell Analysis: A General Overview

Figure 2: Global Prevalence of Cancer, by Type, 2016

Figure 3: The Drug Discovery Process: The Assay Development Stage

Figure 4: Products in Clinical Development and Regulatory Review, 2016

Figure 5: Global Market Shares of the Cancer Cell Analysis, by Product Type, 2017 vs. 2023

Figure 6: Five Major Classes in In Vitro-Based Assays

Figure 7: Estimated New Cases of Leukemia, Lymphoma, and Myeloma, 2018

Figure 8: Basic Components of a Spectrophotometer

Figure 9: Classification of Cell Microarrays

Figure 10: Key Application of Quantitative PCR or Real-Time PCR

Figure 11: End-User Segmentation

Figure 12: Workflow for Gene Expression

Figure 13: Prevalence of Cancer in Major Countries, by Type, 2015

Figure 14: Deaths, by Cancer in Major Countries, 2015

Figure 15: CAR T Cell Therapy in Immuno-Oncology Medicine Development, 2017

Figure 16: CAR T Cell Therapy Mechanism

Figure 17: Private Risk Sharing Contracts Announced, 1990-2017

Figure 18: Market Share for the Drugs Under Development, 2016

Figure 19: Projects in Development Based on Novel Approaches, by Type, 2016

Figure 20: Primary Growth Drivers

Figure 21: Application of Single-Cell Analysis in Cancer Research

Figure 22: Prevalence of Prostate Cancer in the United States

Figure 23: Share of Population with Cancer, by Type, 2016

Figure 24: Workflow for Laboratories Undertaking Molecular Pathology for Cancer Patients from Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Samples

Figure 25: Clinical Use of Molecular Diagnostics

Figure 26: Global Cancer Incidence, by Year, 2005-2016

Figure 27: Cancer Deaths Worldwide, 2006-2016

Figure 28: Subsegments of Cell Imaging Approach

Figure 29: Advantages Offered by Fluorescent In Situ Hybridization

Figure 30: Types of Microscopy Techniques

Figure 31: Advantages Offered by High Content Screening

Figure 32: Global Deaths Due to Leukemia, 2016

Figure 33: Estimated New Cases of Leukemia, Lymphoma and Myeloma in the U.S., 2018

Figure 34: Global Deaths Due to Breast Cancer, 2012-2016

Figure 35: Applications of Cancer Cell Analysis

Figure 36: Types of Cancer Cell Imaging

Figure 37: Workflow for an Imaging-Based Cell Migration Experiment

Figure 38: Cell Viability at Various Concentrations of Anti-Cancer Drug

Figure 39: Mechanism of Cell Signaling

Figure 40: Types of Cell Signaling Pathways

Figure 41: National Cancer Institute (NCI) Cancer Research Funding, by Cancer Type, 2014-2016

Figure 42: Techniques of RNA Expression

Figure 43: Biotechnology R&D Expenditures, by Country, 2011 and 2015

Figure 44: Antitumor Impacts of Innate Immune Cells

Figure 45: Integration of Gene Therapy and Stem Cells for Cancer Treatment

Figure 46: Production Process of CAR T Cells

Figure 47: Flow Cytometry Automated Cancer Cell Analysis Pipeline

Figure 48: Application of Single-Cell Sequencing Technology in Tumor Evolution and Metastasis

Figure 49: Major Breakthroughs in Cancer Research in India

Figure 50: Commonly Diagnosed Cancers in Male, by Cancer Type, 2017

Figure 51: Commonly Diagnosed Cancers in Females, by Cancer Type, 2017

Figure 52: Distribution, by Cancer Type, 2015

Figure 53: Estimated Number of People Living with Cancer in the U.K., by Country, 2015 and 2020

Figure 54: Workflow of Anticancer Drug Discovery

Figure 55: Site-specific Research Funding in the United Kingdom, 2015

Figure 56: Funding of the Research Program in Biology and Basic Sciences for Cancer Research in France, 2007-2015

Figure 57: Estimates of Spain's Cancer Incidence in Men and Women, by Cancer Type, 2015

Figure 58: Keyna's Prevalence of Cancer, by Cancer Type, 2015 and 2016

Figure 59: Industry Process Flow within Cancer Cell Analysis Market

Figure 60: Outline of Cancer Cell Analysis Industry

Figure 61: R&D Phase from Conceptualization to Development

Figure 62: Marketing Matrix for Cancer Cell Analysis Products

Figure 63: Factors Influencing Contracts with Suppliers within the Cancer Cell Analysis Market

Figure 64: Factors Driving M&A Deals Across the Life Science Sector

Figure 65: Generalized Manufacturing Process Flow for Cancer Cell Analysis Products
Figure 66: Global Oncology Therapeutic and Care Spending, 2013-2020

I would like to order

Product name: Cancer Cell Analysis, Instruments, Consumables and Reagents

Product link: <https://marketpublishers.com/r/CE095B09B86EN.html>

Price: US\$ 1,375.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CE095B09B86EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970